These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21300982)

  • 1. c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
    Kollmann K; Heller G; Ott RG; Scheicher R; Zebedin-Brandl E; Schneckenleithner C; Simma O; Warsch W; Eckelhart E; Hoelbl A; Bilban M; Zöchbauer-Müller S; Malumbres M; Sexl V
    Blood; 2011 Apr; 117(15):4065-75. PubMed ID: 21300982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JunB is a gatekeeper for B-lymphoid leukemia.
    Ott RG; Simma O; Kollmann K; Weisz E; Zebedin EM; Schorpp-Kistner M; Heller G; Zöchbauer S; Wagner EF; Freissmuth M; Sexl V
    Oncogene; 2007 Jul; 26(33):4863-71. PubMed ID: 17297445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
    Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
    Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl.
    Chen YJ; Chang LS
    Mol Nutr Food Res; 2012 Sep; 56(9):1398-412. PubMed ID: 22865631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
    Raitano AB; Halpern JR; Hambuch TM; Sawyers CL
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11746-50. PubMed ID: 8524841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role for Gab2 in transformation by BCR/ABL.
    Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
    Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis.
    Zuo B; Li M; Liu Y; Li K; Ma S; Cui M; Qin Y; Zhu H; Pan X; Guo J; Dai Z; Yu W
    Leuk Lymphoma; 2015 Jul; 56(7):2170-81. PubMed ID: 25363403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard.
    Kollmann K; Heller G; Sexl V
    Oncotarget; 2011 May; 2(5):422-7. PubMed ID: 21789792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/CAS9-mediated knockout of Abi1 inhibits p185
    Faulkner J; Jiang P; Farris D; Walker R; Dai Z
    J Hematol Oncol; 2020 Apr; 13(1):34. PubMed ID: 32276588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation.
    Cirinnà M; Trotta R; Salomoni P; Kossev P; Wasik M; Perrotti D; Calabretta B
    Blood; 2000 Dec; 96(12):3915-21. PubMed ID: 11090078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
    Yu W; Sun X; Tang H; Tao Y; Dai Z
    Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Wasik M; Trotta R; Kanakaraj P; Salomoni P; Antonyak M; Martinez R; Majewski M; Wong A; Perussia B; Calabretta B
    Blood; 1998 Jan; 91(2):406-18. PubMed ID: 9427693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
    Nosaka T; Kitamura T
    Exp Hematol; 2002 Jul; 30(7):697-702. PubMed ID: 12135666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
    Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
    Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.
    Jena N; Deng M; Sicinska E; Sicinski P; Daley GQ
    Cancer Res; 2002 Jan; 62(2):535-41. PubMed ID: 11809706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
    Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
    Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
    Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
    Iotti G; Ferrari-Amorotti G; Rosafio C; Corradini F; Lidonnici MR; Ronchetti M; Bardini M; Zhang Y; Martinez R; Blasi F; Calabretta B
    Oncogene; 2007 May; 26(24):3482-91. PubMed ID: 17160016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.